Covered recipient · General Payments record
LORI A LESLIE
Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2021 · Entire year
$119,577.63
78 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2021 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $73,895.00 | 42 |
| Consulting Fee | $29,037.50 | 15 |
| Honoraria | $16,520.00 | 12 |
| Food and Beverage | $115.84 | 8 |
| Travel and Lodging | $9.29 | 1 |
By paying entity
PY2021 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| BeiGene USA, Inc. | $35,484.29 | 18 |
| Kite Pharma, Inc. | $21,200.00 | 9 |
| Epizyme, Inc., | $16,520.00 | 12 |
| AstraZeneca Pharmaceuticals LP | $15,264.99 | 12 |
| Seagen Inc. | $7,462.92 | 6 |
| Pharmacyclics LLC, An AbbVie Company | $6,942.96 | 8 |
| Janssen Scientific Affairs, LLC | $4,972.50 | 2 |
| Janssen Biotech, Inc. | $4,265.00 | 4 |
| Merck Sharp & Dohme Corporation | $4,000.00 | 1 |
| AbbVie Inc. | $3,000.00 | 4 |
| TG THERAPEUTICS, INC. | $450.00 | 1 |
| E.R. Squibb & Sons, L.L.C. | $14.97 | 1 |
Page 2 of 2; records 51–78 of 78 matching records. This page contains 28 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
LORI A LESLIE
NPI 1972746394 · CMS profile ID 362037
Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology
HACKENSACK, NJ
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 2; records 51–78 of 78 matching records. This page contains 28 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1972746394?year=2021&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- LORI A LESLIE, NPI 1972746394, CMS profile ID 362037. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–78 of 78 matching records. This page contains 28 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1972746394?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- APA 7
- IndustryPayments. (2026). LORI A LESLIE, NPI 1972746394, CMS profile ID 362037. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–78 of 78 matching records. This page contains 28 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1972746394?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- Bluebook
- LORI A LESLIE, NPI 1972746394, CMS profile ID 362037, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–78 of 78 matching records. This page contains 28 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1972746394?year=2021&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2021
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30
78 matching records · $119,577.63 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–78 of 78.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| BeiGene USA, Inc. | $1,375.00 | 04/27/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 846696103 | CMS |
| Kite Pharma, Inc. | $1,890.00 | 04/26/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 844416999 | CMS |
| Kite Pharma, Inc. | $1,890.00 | 04/26/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 844417003 | CMS |
| AstraZeneca Pharmaceuticals LP | $1,100.00 | 04/15/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 829585657 | CMS |
| BeiGene USA, Inc. | $1,375.00 | 04/13/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 846696101 | CMS |
| Pharmacyclics LLC, An AbbVie Company | $18.73 | 04/09/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 781017237 | CMS |
| Kite Pharma, Inc. | $2,910.00 | 04/07/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 844417007 | CMS |
| Pharmacyclics LLC, An AbbVie Company | $1,500.00 | 04/06/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 781017235 | CMS |
| AstraZeneca Pharmaceuticals LP | $14.99 | 03/31/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 829725269 | CMS |
| Epizyme, Inc., | $2,655.00 | 03/31/2021 | Honoraria | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 832341293 | CMS |
| BeiGene USA, Inc. | $1,650.00 | 03/29/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 846696105 | CMS |
| Pharmacyclics LLC, An AbbVie Company | $6.00 | 03/16/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 781017233 | CMS |
| AstraZeneca Pharmaceuticals LP | $300.00 | 03/09/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 830016101 | CMS |
| BeiGene USA, Inc. | $1,375.00 | 03/08/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 846696109 | CMS |
| Seagen Inc. | $1,235.00 | 02/25/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 832185947 | CMS |
| BeiGene USA, Inc. | $1,375.00 | 02/22/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 846696107 | CMS |
| Seagen Inc. | $1,100.00 | 02/10/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 832185927 | CMS |
| Kite Pharma, Inc. | $2,600.00 | 02/09/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 844416983 | CMS |
| AstraZeneca Pharmaceuticals LP | $1,100.00 | 02/07/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 829537305 | CMS |
| BeiGene USA, Inc. | $1,375.00 | 02/05/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 846696095 | CMS |
| BeiGene USA, Inc. | $3,850.00 | 02/03/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 846696099 | CMS |
| AstraZeneca Pharmaceuticals LP | $1,665.00 | 02/02/2021 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 830053217 | CMS |
| Epizyme, Inc., | $1,180.00 | 01/29/2021 | Honoraria | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 832341289 | CMS |
| Epizyme, Inc., | $1,180.00 | 01/29/2021 | Honoraria | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 832341291 | CMS |
| BeiGene USA, Inc. | $1,375.00 | 01/28/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 846696097 | CMS |
| Epizyme, Inc., | $2,065.00 | 01/28/2021 | Honoraria | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 832341287 | CMS |
| Janssen Scientific Affairs, LLC | $1,950.00 | 01/04/2021 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788881977 | CMS |
| Epizyme, Inc., | $1,770.00 | 01/01/2021 | Honoraria | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 832341285 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $1,697,787.14 | 162 |
| PY2024 | Principal investigator | $2,248,943.87 | 274 |
| PY2023 | Principal investigator | $2,557,435.47 | 271 |
| PY2022 | Principal investigator | $1,660,583.78 | 163 |
| PY2021 | Recipient | $15.58 | 1 |
| PY2021 | Principal investigator | $1,246,262.05 | 125 |
| PY2020 | Principal investigator | $1,149,818.73 | 57 |
| PY2019 | Recipient | $1,306.79 | 6 |
| PY2019 | Principal investigator | $658,218.85 | 28 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
162 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $600.00 | 12/24/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | AN OPEN-LABEL STUDY TO ASSESS THE ANTI-TUMOR ACTIVITY AND SAFETY OF REGN1979, AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA | No dispute reported | 06/30/2026 | 1184128450 |
| Principal investigator 1 | BeOne Medicines Ltd. | $2,604.00 | 12/23/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1190330845 |
| Principal investigator 1 | Genmab A/S | $282.00 | 12/22/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. | No dispute reported | 06/30/2026 | 1235923675 |
| Principal investigator 1 | Genmab A/S | $2,720.00 | 12/22/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. | No dispute reported | 06/30/2026 | 1235923708 |
| Principal investigator 1 | Genmab A/S | $20,509.00 | 12/19/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. | No dispute reported | 06/30/2026 | 1235923726 |
| Principal investigator 1 | Genmab A/S | $1,798.00 | 12/19/2025 | Non-covered Recipient Entity WCG IRB | A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. | No dispute reported | 06/30/2026 | 1235940385 |
| Principal investigator 1 | Genmab A/S | $1,589.00 | 12/19/2025 | Non-covered Recipient Entity WCG IRB | A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. | No dispute reported | 06/30/2026 | 1235940394 |
| Principal investigator 1 | Genmab A/S | $2,759.00 | 12/19/2025 | Non-covered Recipient Entity WCG IRB | A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. | No dispute reported | 06/30/2026 | 1235940398 |
| Principal investigator 1 | Kite Pharma, Inc. | $75.00 | 12/16/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A PHASE 2 OPEN-LABEL, MULTICENTER STUDY EVALUATING THE SAFETY AND EFFICACY OF AXICABTAGENE-CILOLEUCEL CONCOMITANT WITH PROPHYLACTIC STEROIDS IN SUBJECTS WITH RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA IN THE OUTPATIENT SETTING | No dispute reported | 06/30/2026 | 1212066947 |
| Principal investigator 1 | Genmab A/S | $6,825.00 | 12/15/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. | No dispute reported | 06/30/2026 | 1235923671 |
| Principal investigator 1 | Genmab A/S | $6,842.00 | 12/15/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. | No dispute reported | 06/30/2026 | 1235923714 |
| Principal investigator 1 | Genmab A/S | $2,809.00 | 12/15/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. | No dispute reported | 06/30/2026 | 1235923716 |
| Principal investigator 1 | Genmab A/S | $480.00 | 12/15/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. | No dispute reported | 06/30/2026 | 1235923723 |
| Principal investigator 1 | Genmab A/S | $259,350.00 | 12/12/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. | No dispute reported | 06/30/2026 | 1235923690 |
| Principal investigator 1 | Genmab A/S | $365.00 | 12/12/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. | No dispute reported | 06/30/2026 | 1235923702 |
| Principal investigator 1 | Genmab A/S | $1,125.00 | 12/12/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. | No dispute reported | 06/30/2026 | 1235923705 |
| Principal investigator 1 | Genmab A/S | $87,079.00 | 12/12/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. | No dispute reported | 06/30/2026 | 1235923729 |
| Principal investigator 1 | Genmab A/S | $338.00 | 12/12/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. | No dispute reported | 06/30/2026 | 1235923740 |
| Principal investigator 1 | Genmab A/S | $2,387.00 | 12/12/2025 | Non-covered Recipient Entity HACKENSACK MERIDIAN HEALTH HACKENSACK UNIVERSITY MEDICAL CENTER | A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody-CD3 X CD20) in Relapsed/Refractory Chronic Lymphocytic Leukemia. | No dispute reported | 06/30/2026 | 1235930481 |
| Principal investigator 1 | Genmab A/S | $6,252.00 | 12/12/2025 | Non-covered Recipient Entity HACKENSACK MERIDIAN HEALTH HACKENSACK UNIVERSITY MEDICAL CENTER | A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody-CD3 X CD20) in Relapsed/Refractory Chronic Lymphocytic Leukemia. | No dispute reported | 06/30/2026 | 1235930488 |
| Principal investigator 1 | Genmab A/S | $2,387.00 | 12/12/2025 | Non-covered Recipient Entity HACKENSACK MERIDIAN HEALTH HACKENSACK UNIVERSITY MEDICAL CENTER | A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody-CD3 X CD20) in Relapsed/Refractory Chronic Lymphocytic Leukemia. | No dispute reported | 06/30/2026 | 1235930495 |
| Principal investigator 1 | Genmab A/S | $2,387.00 | 12/12/2025 | Non-covered Recipient Entity HACKENSACK MERIDIAN HEALTH HACKENSACK UNIVERSITY MEDICAL CENTER | A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody-CD3 X CD20) in Relapsed/Refractory Chronic Lymphocytic Leukemia. | No dispute reported | 06/30/2026 | 1235930499 |
| Principal investigator 1 | Genmab A/S | $2,387.00 | 12/12/2025 | Non-covered Recipient Entity HACKENSACK MERIDIAN HEALTH HACKENSACK UNIVERSITY MEDICAL CENTER | A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody-CD3 X CD20) in Relapsed/Refractory Chronic Lymphocytic Leukemia. | No dispute reported | 06/30/2026 | 1235930503 |
| Principal investigator 1 | Genmab A/S | $900.00 | 12/03/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. | No dispute reported | 06/30/2026 | 1235923679 |
| Principal investigator 1 | Genmab A/S | $1,800.00 | 12/03/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. | No dispute reported | 06/30/2026 | 1235923694 |
| Principal investigator 1 | Genmab A/S | $1,000.00 | 12/03/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. | No dispute reported | 06/30/2026 | 1235923733 |
| Principal investigator 1 | Genmab A/S | $213.00 | 11/21/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. | No dispute reported | 06/30/2026 | 1235923683 |
| Principal investigator 1 | Genmab A/S | $2,720.00 | 11/21/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. | No dispute reported | 06/30/2026 | 1235923720 |
| Principal investigator 1 | Genmab A/S | $213.00 | 11/21/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. | No dispute reported | 06/30/2026 | 1235923736 |
| Principal investigator 1 | Genmab A/S | $2,720.00 | 11/21/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. | No dispute reported | 06/30/2026 | 1235923743 |
| Principal investigator 1 | BeOne Medicines Ltd. | $23,931.00 | 11/12/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1190330899 |
| Principal investigator 1 | Genmab A/S | $107,583.00 | 11/05/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. | No dispute reported | 06/30/2026 | 1235923687 |
| Principal investigator 1 | Genmab A/S | $6,825.00 | 11/05/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. | No dispute reported | 06/30/2026 | 1235923698 |
| Principal investigator 1 | Genmab A/S | $2,704.00 | 11/05/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. | No dispute reported | 06/30/2026 | 1235923711 |
| Principal investigator 1 | BeOne Medicines Ltd. | $1,920.00 | 10/28/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1190330847 |
| Principal investigator 1 | Kite Pharma, Inc. | $41,538.00 | 10/28/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A PHASE 2 OPEN-LABEL, MULTICENTER STUDY EVALUATING THE SAFETY AND EFFICACY OF AXICABTAGENE-CILOLEUCEL CONCOMITANT WITH PROPHYLACTIC STEROIDS IN SUBJECTS WITH RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA IN THE OUTPATIENT SETTING | No dispute reported | 06/30/2026 | 1212066943 |
| Principal investigator 1 | Genmab A/S | $2,720.00 | 10/24/2025 | Non-covered Recipient Entity HACKENSACK MERIDIAN HEALTH HACKENSACK UNIVERSITY MEDICAL CENTER | A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. | No dispute reported | 06/30/2026 | 1235930492 |
| Principal investigator 1 | Genmab A/S | $213.00 | 10/24/2025 | Non-covered Recipient Entity HACKENSACK MERIDIAN HEALTH HACKENSACK UNIVERSITY MEDICAL CENTER | A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. | No dispute reported | 06/30/2026 | 1235930507 |
| Principal investigator 1 | Genmab A/S | $2,720.00 | 10/24/2025 | Non-covered Recipient Entity HACKENSACK MERIDIAN HEALTH HACKENSACK UNIVERSITY MEDICAL CENTER | A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. | No dispute reported | 06/30/2026 | 1235930514 |
| Principal investigator 1 | Genmab A/S | $2,720.00 | 10/02/2025 | Non-covered Recipient Entity HACKENSACK MERIDIAN HEALTH HACKENSACK UNIVERSITY MEDICAL CENTER | A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. | No dispute reported | 06/30/2026 | 1235930484 |
| Principal investigator 1 | Genmab A/S | $480.00 | 10/02/2025 | Non-covered Recipient Entity HACKENSACK MERIDIAN HEALTH HACKENSACK UNIVERSITY MEDICAL CENTER | A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody-CD3 X CD20) in Relapsed/Refractory Chronic Lymphocytic Leukemia. | No dispute reported | 06/30/2026 | 1235930510 |
| Principal investigator 1 | BeOne Medicines Ltd. | $2,000.00 | 09/23/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1190330885 |
| Principal investigator 1 | BeOne Medicines Ltd. | $5,425.00 | 09/23/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1190330889 |
| Principal investigator 1 | BeOne Medicines Ltd. | $5,961.00 | 09/23/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1190330897 |
| Principal investigator 1 | Genmab A/S | $480.00 | 09/08/2025 | Non-covered Recipient Entity HACKENSACK MERIDIAN HEALTH HACKENSACK UNIVERSITY MEDICAL CENTER | A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody-CD3 X CD20) in Relapsed/Refractory Chronic Lymphocytic Leukemia. | No dispute reported | 06/30/2026 | 1235930478 |
| Principal investigator 1 | BeOne Medicines Ltd. | $3,287.00 | 09/02/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1190330843 |
| Principal investigator 1 | BeOne Medicines Ltd. | $600.00 | 09/02/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1190330891 |
| Principal investigator 1 | BeOne Medicines Ltd. | $1,200.00 | 09/02/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1190330893 |
| Principal investigator 1 | Genmab A/S | $1,300.00 | 08/26/2025 | Non-covered Recipient Entity HACKENSACK MERIDIAN HEALTH HACKENSACK UNIVERSITY MEDICAL CENTER | A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody-CD3 X CD20) in Relapsed/Refractory Chronic Lymphocytic Leukemia. | No dispute reported | 06/30/2026 | 1235930450 |
| Principal investigator 1 | Kite Pharma, Inc. | $3,989.00 | 08/26/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (ZUMA 5) | No dispute reported | 06/30/2026 | 1212066937 |
| Principal investigator 1 | Genmab A/S | $778.00 | 08/20/2025 | Non-covered Recipient Entity HACKENSACK MERIDIAN HEALTH HACKENSACK UNIVERSITY MEDICAL CENTER | A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. | No dispute reported | 06/30/2026 | 1235930447 |
| Principal investigator 1 | Genmab A/S | $213.00 | 08/20/2025 | Non-covered Recipient Entity HACKENSACK MERIDIAN HEALTH HACKENSACK UNIVERSITY MEDICAL CENTER | A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. | No dispute reported | 06/30/2026 | 1235930470 |
| Principal investigator 1 | Kite Pharma, Inc. | $2,907.00 | 08/19/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A PHASE 2 OPEN-LABEL, MULTICENTER STUDY EVALUATING THE SAFETY AND EFFICACY OF AXICABTAGENE-CILOLEUCEL CONCOMITANT WITH PROPHYLACTIC STEROIDS IN SUBJECTS WITH RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA IN THE OUTPATIENT SETTING | No dispute reported | 06/30/2026 | 1212066932 |
| Principal investigator 1 | Acerta Pharma LLC | $1,864.00 | 08/13/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | a randomized,multicenter,open label,3 arm phase 3 study of obinutuzumab in combination with chlorambucil,ACP 196 in combination with obinutuzumaband ACP 196 monotherapy in subjects with previously untreated chronic lymphocytic leukemia | No dispute reported | 06/30/2026 | 1185538392 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $750.00 | 08/13/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | AN OPEN-LABEL STUDY TO ASSESS THE ANTI-TUMOR ACTIVITY AND SAFETY OF REGN1979, AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA | No dispute reported | 06/30/2026 | 1184127944 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $16,775.01 | 08/13/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | AN OPEN-LABEL STUDY TO ASSESS THE ANTI-TUMOR ACTIVITY AND SAFETY OF REGN1979, AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA | No dispute reported | 06/30/2026 | 1184127946 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,731.00 | 08/12/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | AN OPEN-LABEL STUDY TO ASSESS THE ANTI-TUMOR ACTIVITY AND SAFETY OF REGN1979, AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA | No dispute reported | 06/30/2026 | 1184127942 |
| Principal investigator 1 | Genmab A/S | $1,300.00 | 08/06/2025 | Non-covered Recipient Entity HACKENSACK MERIDIAN HEALTH HACKENSACK UNIVERSITY MEDICAL CENTER | A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. | No dispute reported | 06/30/2026 | 1235930435 |
| Principal investigator 1 | Genmab A/S | $500.00 | 08/06/2025 | Non-covered Recipient Entity HACKENSACK MERIDIAN HEALTH HACKENSACK UNIVERSITY MEDICAL CENTER | A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. | No dispute reported | 06/30/2026 | 1235930466 |
| Principal investigator 1 | BeOne Medicines Ltd. | $600.00 | 08/05/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1190330887 |
| Principal investigator 1 | BeOne Medicines Ltd. | $1,586.00 | 08/05/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1190330895 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $600.00 | 07/25/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | AN OPEN-LABEL STUDY TO ASSESS THE ANTI-TUMOR ACTIVITY AND SAFETY OF REGN1979, AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA | No dispute reported | 06/30/2026 | 1184127928 |
| Principal investigator 1 | Genmab A/S | $2,720.00 | 07/23/2025 | Non-covered Recipient Entity HACKENSACK MERIDIAN HEALTH HACKENSACK UNIVERSITY MEDICAL CENTER | A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. | No dispute reported | 06/30/2026 | 1235930458 |
| Principal investigator 1 | Genmab A/S | $2,720.00 | 07/23/2025 | Non-covered Recipient Entity HACKENSACK MERIDIAN HEALTH HACKENSACK UNIVERSITY MEDICAL CENTER | A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. | No dispute reported | 06/30/2026 | 1235930462 |
| Principal investigator 1 | Kite Pharma, Inc. | $1,386.00 | 07/22/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A PHASE 2 OPEN-LABEL, MULTICENTER STUDY EVALUATING THE SAFETY AND EFFICACY OF AXICABTAGENE-CILOLEUCEL CONCOMITANT WITH PROPHYLACTIC STEROIDS IN SUBJECTS WITH RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA IN THE OUTPATIENT SETTING | No dispute reported | 06/30/2026 | 1212066926 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,078.72 | 07/22/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | AN OPEN-LABEL STUDY TO ASSESS THE ANTI-TUMOR ACTIVITY AND SAFETY OF REGN1979, AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA | No dispute reported | 06/30/2026 | 1184127924 |
| Principal investigator 1 | Kite Pharma, Inc. | $354.00 | 07/15/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel in Adults with Rare B-cell Malignancies (ZUMA-25) - Substudy B - Relapsed/Refractory Richter Transformation | No dispute reported | 06/30/2026 | 1212066832 |
| Principal investigator 1 | Kite Pharma, Inc. | $820.00 | 07/08/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel in Adults with Rare B-cell Malignancies (ZUMA-25) - Substudy B - Relapsed/Refractory Richter Transformation | No dispute reported | 06/30/2026 | 1212066826 |
| Principal investigator 1 | Genmab A/S | $609.00 | 07/07/2025 | Non-covered Recipient Entity HACKENSACK MERIDIAN HEALTH HACKENSACK UNIVERSITY MEDICAL CENTER | A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. | No dispute reported | 06/30/2026 | 1235930439 |
| Principal investigator 1 | Genmab A/S | $4,954.00 | 07/07/2025 | Non-covered Recipient Entity HACKENSACK MERIDIAN HEALTH HACKENSACK UNIVERSITY MEDICAL CENTER | A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. | No dispute reported | 06/30/2026 | 1235930442 |
| Principal investigator 1 | Genmab A/S | $1,690.00 | 07/07/2025 | Non-covered Recipient Entity HACKENSACK MERIDIAN HEALTH HACKENSACK UNIVERSITY MEDICAL CENTER | A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. | No dispute reported | 06/30/2026 | 1235930454 |
| Principal investigator 1 | Genmab A/S | $20,526.00 | 07/07/2025 | Non-covered Recipient Entity HACKENSACK MERIDIAN HEALTH HACKENSACK UNIVERSITY MEDICAL CENTER | A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. | No dispute reported | 06/30/2026 | 1235930474 |
| Principal investigator 1 | BeOne Medicines Ltd. | $1,200.00 | 07/01/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1190330883 |
| Principal investigator 1 | Genmab A/S | $213.00 | 06/26/2025 | Non-covered Recipient Entity HACKENSACK MERIDIAN HEALTH HACKENSACK UNIVERSITY MEDICAL CENTER | A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. | No dispute reported | 06/30/2026 | 1235930388 |
| Principal investigator 1 | Genmab A/S | $2,720.00 | 06/26/2025 | Non-covered Recipient Entity HACKENSACK MERIDIAN HEALTH HACKENSACK UNIVERSITY MEDICAL CENTER | A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. | No dispute reported | 06/30/2026 | 1235930398 |
| Principal investigator 1 | Genmab A/S | $400.00 | 06/26/2025 | Non-covered Recipient Entity HACKENSACK MERIDIAN HEALTH HACKENSACK UNIVERSITY MEDICAL CENTER | A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. | No dispute reported | 06/30/2026 | 1235930406 |
| Principal investigator 1 | Genmab A/S | $153.40 | 06/26/2025 | Non-covered Recipient Entity HACKENSACK MERIDIAN HEALTH HACKENSACK UNIVERSITY MEDICAL CENTER | A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. | No dispute reported | 06/30/2026 | 1235930410 |
| Principal investigator 1 | Genmab A/S | $213.00 | 06/26/2025 | Non-covered Recipient Entity HACKENSACK MERIDIAN HEALTH HACKENSACK UNIVERSITY MEDICAL CENTER | A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. | No dispute reported | 06/30/2026 | 1235930418 |
| Principal investigator 1 | Genmab A/S | $676.00 | 06/26/2025 | Non-covered Recipient Entity HACKENSACK MERIDIAN HEALTH HACKENSACK UNIVERSITY MEDICAL CENTER | A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. | No dispute reported | 06/30/2026 | 1235930426 |
| Principal investigator 1 | Genmab A/S | $2,720.00 | 06/26/2025 | Non-covered Recipient Entity HACKENSACK MERIDIAN HEALTH HACKENSACK UNIVERSITY MEDICAL CENTER | A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. | No dispute reported | 06/30/2026 | 1235930430 |
| Principal investigator 1 | BeOne Medicines Ltd. | $3,230.00 | 06/24/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Phase 1a/1b Open-Label Dose Escalation and Expansion Study of Bcl-2 Inhibitor BGB-11417 in Patients With Mature B-Cell Malignancies | No dispute reported | 06/30/2026 | 1190326044 |
| Principal investigator 1 | BeOne Medicines Ltd. | $2,200.00 | 06/24/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Phase 1a/1b Open-Label Dose Escalation and Expansion Study of Bcl-2 Inhibitor BGB-11417 in Patients With Mature B-Cell Malignancies | No dispute reported | 06/30/2026 | 1190326922 |
| Principal investigator 1 | Kite Pharma, Inc. | $2,000.00 | 06/24/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A PHASE 2 OPEN-LABEL, MULTICENTER STUDY EVALUATING THE SAFETY AND EFFICACY OF AXICABTAGENE-CILOLEUCEL CONCOMITANT WITH PROPHYLACTIC STEROIDS IN SUBJECTS WITH RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA IN THE OUTPATIENT SETTING | No dispute reported | 06/30/2026 | 1212066921 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,800.00 | 06/19/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | AN OPEN-LABEL STUDY TO ASSESS THE ANTI-TUMOR ACTIVITY AND SAFETY OF REGN1979, AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA | No dispute reported | 06/30/2026 | 1184127526 |
| Principal investigator 1 | Kite Pharma, Inc. | $800.00 | 06/17/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A PHASE 2 OPEN-LABEL, MULTICENTER STUDY EVALUATING THE SAFETY AND EFFICACY OF AXICABTAGENE-CILOLEUCEL CONCOMITANT WITH PROPHYLACTIC STEROIDS IN SUBJECTS WITH RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA IN THE OUTPATIENT SETTING | No dispute reported | 06/30/2026 | 1212066917 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $300.00 | 06/13/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | AN OPEN-LABEL STUDY TO ASSESS THE ANTI-TUMOR ACTIVITY AND SAFETY OF REGN1979, AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA | No dispute reported | 06/30/2026 | 1184127520 |
| Principal investigator 1 | BeOne Medicines Ltd. | $4,550.00 | 06/10/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1190330901 |
| Principal investigator 1 | Kite Pharma, Inc. | $780.00 | 06/03/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Phase 2 Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Axicabtagene Ciloleucel in Combination with Rituximab or Lenalidomide in Subjects with Refractory Large B-Cell Lymphoma (ZUMA-14) | No dispute reported | 06/30/2026 | 1212066906 |
| Principal investigator 1 | Kite Pharma, Inc. | $1,750.00 | 06/03/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel versus Standard of Care Therapy in Subjects with Relapsed/Refractory Diffuse Large B Cell Lymphoma (ZUMA 7) | No dispute reported | 06/30/2026 | 1212066910 |
| Principal investigator 1 | BeOne Medicines Ltd. | $3,287.00 | 05/30/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1190330859 |
| Principal investigator 1 | BeiGene, Ltd. | $6,786.00 | 05/20/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Phase 1a/1b Open-Label Dose Escalation and Expansion Study of Bcl-2 Inhibitor BGB-11417 in Patients With Mature B-Cell Malignancies | No dispute reported | 06/30/2026 | 1190321196 |
| Principal investigator 1 | BeiGene, Ltd. | $600.00 | 05/20/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1190321700 |
| Principal investigator 1 | Kite Pharma, Inc. | $2,531.00 | 05/20/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (ZUMA 5) | No dispute reported | 06/30/2026 | 1212066892 |
| Principal investigator 1 | Kite Pharma, Inc. | $9,521.55 | 05/20/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel versus Standard of Care Therapy in Subjects with Relapsed/Refractory Diffuse Large B Cell Lymphoma (ZUMA 7) | No dispute reported | 06/30/2026 | 1212066898 |
| Principal investigator 1 | BeiGene, Ltd. | $2,400.00 | 05/12/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Phase 1a/1b Open-Label Dose Escalation and Expansion Study of Bcl-2 Inhibitor BGB-11417 in Patients With Mature B-Cell Malignancies | No dispute reported | 06/30/2026 | 1190322436 |
| Principal investigator 1 | Genmab A/S | $960.00 | 05/02/2025 | Non-covered Recipient Entity HACKENSACK MERIDIAN HEALTH HACKENSACK UNIVERSITY MEDICAL CENTER | A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody-CD3 X CD20) in Relapsed/Refractory Chronic Lymphocytic Leukemia. | No dispute reported | 06/30/2026 | 1235930391 |
| Principal investigator 1 | Genmab A/S | $960.00 | 05/02/2025 | Non-covered Recipient Entity HACKENSACK MERIDIAN HEALTH HACKENSACK UNIVERSITY MEDICAL CENTER | A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody-CD3 X CD20) in Relapsed/Refractory Chronic Lymphocytic Leukemia. | No dispute reported | 06/30/2026 | 1235930414 |
| Principal investigator 1 | Kite Pharma, Inc. | $600.00 | 05/01/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (ZUMA 5) | No dispute reported | 06/30/2026 | 1212066886 |
| Principal investigator 1 | BeiGene, Ltd. | $3,541.00 | 04/29/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1190321708 |
| Principal investigator 1 | Genmab A/S | $2,720.00 | 04/23/2025 | Non-covered Recipient Entity HACKENSACK MERIDIAN HEALTH HACKENSACK UNIVERSITY MEDICAL CENTER | A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. | No dispute reported | 06/30/2026 | 1235930402 |
| Principal investigator 1 | Kite Pharma, Inc. | $7,398.00 | 04/22/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A PHASE 2 OPEN-LABEL, MULTICENTER STUDY EVALUATING THE SAFETY AND EFFICACY OF AXICABTAGENE-CILOLEUCEL CONCOMITANT WITH PROPHYLACTIC STEROIDS IN SUBJECTS WITH RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA IN THE OUTPATIENT SETTING | No dispute reported | 06/30/2026 | 1212066880 |
| Principal investigator 1 | BeiGene, Ltd. | $4,110.00 | 04/17/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Phase 1a/1b Open-Label Dose Escalation and Expansion Study of Bcl-2 Inhibitor BGB-11417 in Patients With Mature B-Cell Malignancies | No dispute reported | 06/30/2026 | 1190321194 |
| Principal investigator 1 | BeiGene, Ltd. | $31,440.00 | 04/08/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1190323830 |
| Principal investigator 1 | Eli Lilly and Company | $426.40 | 04/08/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF FIXED DURATION PIRTOBRUTINIB (LOXO-305) PLUS VENETOCLAX AND RITUXIMAB VERSUS VENETOCLAX AND RITUXIMAB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (BRUIN CLL-322) | No dispute reported | 06/30/2026 | 1187873721 |
| Principal investigator 1 | Kite Pharma, Inc. | $750.00 | 04/08/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A PHASE 2 OPEN-LABEL, MULTICENTER STUDY EVALUATING THE SAFETY AND EFFICACY OF AXICABTAGENE-CILOLEUCEL CONCOMITANT WITH PROPHYLACTIC STEROIDS IN SUBJECTS WITH RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA IN THE OUTPATIENT SETTING | No dispute reported | 06/30/2026 | 1212066873 |
| Principal investigator 1 | BeiGene, Ltd. | $31,440.00 | 04/07/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1190322190 |
| Principal investigator 1 | Genmab A/S | $213.00 | 04/02/2025 | Non-covered Recipient Entity HACKENSACK MERIDIAN HEALTH HACKENSACK UNIVERSITY MEDICAL CENTER | A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. | No dispute reported | 06/30/2026 | 1235930394 |
| Principal investigator 1 | Genmab A/S | $2,720.00 | 04/02/2025 | Non-covered Recipient Entity HACKENSACK MERIDIAN HEALTH HACKENSACK UNIVERSITY MEDICAL CENTER | A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. | No dispute reported | 06/30/2026 | 1235930422 |
| Principal investigator 1 | BeiGene, Ltd. | $645.00 | 04/01/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1190321706 |
| Principal investigator 1 | BeiGene, Ltd. | $2,600.00 | 03/18/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1190321702 |
| Principal investigator 1 | BeiGene, Ltd. | $1,585.00 | 03/18/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1190321704 |
| Principal investigator 1 | BeiGene, Ltd. | $560.25 | 03/18/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1190324702 |
| Principal investigator 1 | Kite Pharma, Inc. | $3,239.00 | 03/18/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A PHASE 2 OPEN-LABEL, MULTICENTER STUDY EVALUATING THE SAFETY AND EFFICACY OF AXICABTAGENE-CILOLEUCEL CONCOMITANT WITH PROPHYLACTIC STEROIDS IN SUBJECTS WITH RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA IN THE OUTPATIENT SETTING | No dispute reported | 06/30/2026 | 1212066866 |
| Principal investigator 1 | Genmab A/S | $543.00 | 03/14/2025 | Non-covered Recipient Entity HACKENSACK MERIDIAN HEALTH HACKENSACK UNIVERSITY MEDICAL CENTER | A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody-CD3 X CD20) in Relapsed/Refractory Chronic Lymphocytic Leukemia. | No dispute reported | 06/30/2026 | 1235930316 |
| Principal investigator 1 | Genmab A/S | $543.00 | 03/14/2025 | Non-covered Recipient Entity HACKENSACK MERIDIAN HEALTH HACKENSACK UNIVERSITY MEDICAL CENTER | A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody-CD3 X CD20) in Relapsed/Refractory Chronic Lymphocytic Leukemia. | No dispute reported | 06/30/2026 | 1235930332 |
| Principal investigator 1 | Genmab A/S | $543.00 | 03/14/2025 | Non-covered Recipient Entity HACKENSACK MERIDIAN HEALTH HACKENSACK UNIVERSITY MEDICAL CENTER | A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody-CD3 X CD20) in Relapsed/Refractory Chronic Lymphocytic Leukemia. | No dispute reported | 06/30/2026 | 1235930340 |
| Principal investigator 1 | Genmab A/S | $543.00 | 03/14/2025 | Non-covered Recipient Entity HACKENSACK MERIDIAN HEALTH HACKENSACK UNIVERSITY MEDICAL CENTER | A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody-CD3 X CD20) in Relapsed/Refractory Chronic Lymphocytic Leukemia. | No dispute reported | 06/30/2026 | 1235930344 |
| Principal investigator 1 | Genmab A/S | $543.00 | 03/14/2025 | Non-covered Recipient Entity HACKENSACK MERIDIAN HEALTH HACKENSACK UNIVERSITY MEDICAL CENTER | A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody-CD3 X CD20) in Relapsed/Refractory Chronic Lymphocytic Leukemia. | No dispute reported | 06/30/2026 | 1235930349 |
| Principal investigator 1 | Genmab A/S | $543.00 | 03/14/2025 | Non-covered Recipient Entity HACKENSACK MERIDIAN HEALTH HACKENSACK UNIVERSITY MEDICAL CENTER | A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody-CD3 X CD20) in Relapsed/Refractory Chronic Lymphocytic Leukemia. | No dispute reported | 06/30/2026 | 1235930361 |
| Principal investigator 1 | Genmab A/S | $543.00 | 03/14/2025 | Non-covered Recipient Entity HACKENSACK MERIDIAN HEALTH HACKENSACK UNIVERSITY MEDICAL CENTER | A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody-CD3 X CD20) in Relapsed/Refractory Chronic Lymphocytic Leukemia. | No dispute reported | 06/30/2026 | 1235930369 |
| Principal investigator 1 | BeiGene, Ltd. | $62,880.00 | 03/12/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Phase 1a/1b Open-Label Dose Escalation and Expansion Study of Bcl-2 Inhibitor BGB-11417 in Patients With Mature B-Cell Malignancies | No dispute reported | 06/30/2026 | 1190321770 |
| Principal investigator 1 | BeiGene, Ltd. | $7,724.00 | 03/11/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Phase 1a/1b Open-Label Dose Escalation and Expansion Study of Bcl-2 Inhibitor BGB-11417 in Patients With Mature B-Cell Malignancies | No dispute reported | 06/30/2026 | 1190321192 |
| Principal investigator 1 | Genmab A/S | $2,720.00 | 03/03/2025 | Non-covered Recipient Entity HACKENSACK MERIDIAN HEALTH HACKENSACK UNIVERSITY MEDICAL CENTER | A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. | No dispute reported | 06/30/2026 | 1235930354 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $101,067.77 | 02/26/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Modular Phase I and II Open-label Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD5492, a T cell-engaging Antibody Targeting CD20 in Subjects with Relapsed or Refractory B-Cell Malignancies (TITANium) | No dispute reported | 06/30/2026 | 1185538396 |
| Principal investigator 1 | BeiGene, Ltd. | $3,287.00 | 02/25/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1190321548 |
| Principal investigator 1 | Kite Pharma, Inc. | $3,450.00 | 02/19/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel in Adults with Rare B-cell Malignancies (ZUMA-25) - Substudy B - Relapsed/Refractory Richter Transformation | No dispute reported | 06/30/2026 | 1212066819 |
| Principal investigator 1 | Kite Pharma, Inc. | $1,386.00 | 02/19/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A PHASE 2 OPEN-LABEL, MULTICENTER STUDY EVALUATING THE SAFETY AND EFFICACY OF AXICABTAGENE-CILOLEUCEL CONCOMITANT WITH PROPHYLACTIC STEROIDS IN SUBJECTS WITH RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA IN THE OUTPATIENT SETTING | No dispute reported | 06/30/2026 | 1212066864 |
| Principal investigator 1 | BeiGene, Ltd. | $4,547.00 | 02/18/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Phase 1a/1b Open-Label Dose Escalation and Expansion Study of Bcl-2 Inhibitor BGB-11417 in Patients With Mature B-Cell Malignancies | No dispute reported | 06/30/2026 | 1190321190 |
| Principal investigator 1 | Genmab A/S | $381.00 | 02/14/2025 | Non-covered Recipient Entity HACKENSACK MERIDIAN HEALTH HACKENSACK UNIVERSITY MEDICAL CENTER | A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody-CD3 X CD20) in Relapsed/Refractory Chronic Lymphocytic Leukemia. | No dispute reported | 06/30/2026 | 1235930311 |
| Principal investigator 1 | Acerta Pharma LLC | $52,589.29 | 02/13/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Randomized, Multicenter, Open-Label, 3 Arm Phase 3 Study of Obinutuzumab in Combination with Chlorambucil, ACP-196 in Combination with Obinutuzumab, and ACP-196 Monotherapy in Subjects with Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1185538394 |
| Principal investigator 1 | Genmab A/S | $213.00 | 02/03/2025 | Non-covered Recipient Entity HACKENSACK MERIDIAN HEALTH HACKENSACK UNIVERSITY MEDICAL CENTER | A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. | No dispute reported | 06/30/2026 | 1235930328 |
| Principal investigator 1 | Genmab A/S | $2,720.00 | 02/03/2025 | Non-covered Recipient Entity HACKENSACK MERIDIAN HEALTH HACKENSACK UNIVERSITY MEDICAL CENTER | A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. | No dispute reported | 06/30/2026 | 1235930346 |
| Principal investigator 1 | Genmab A/S | $2,720.00 | 02/03/2025 | Non-covered Recipient Entity HACKENSACK MERIDIAN HEALTH HACKENSACK UNIVERSITY MEDICAL CENTER | A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. | No dispute reported | 06/30/2026 | 1235930365 |
| Principal investigator 1 | Genmab A/S | $213.00 | 02/03/2025 | Non-covered Recipient Entity HACKENSACK MERIDIAN HEALTH HACKENSACK UNIVERSITY MEDICAL CENTER | A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. | No dispute reported | 06/30/2026 | 1235930380 |
| Principal investigator 1 | BeiGene, Ltd. | $10,962.00 | 01/28/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Phase 1a/1b Open-Label Dose Escalation and Expansion Study of Bcl-2 Inhibitor BGB-11417 in Patients With Mature B-Cell Malignancies | No dispute reported | 06/30/2026 | 1190321188 |
| Principal investigator 1 | BeiGene, Ltd. | $7,559.00 | 01/28/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1190321546 |
| Principal investigator 1 | BeiGene, Ltd. | $645.00 | 01/28/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1190324704 |
| Principal investigator 1 | Kite Pharma, Inc. | $440.00 | 01/28/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel in Adults with Rare B-cell Malignancies (ZUMA-25) - Substudy B - Relapsed/Refractory Richter Transformation | No dispute reported | 06/30/2026 | 1212066804 |
| Principal investigator 1 | Kite Pharma, Inc. | $2,075.00 | 01/28/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel in Adults with Rare B-cell Malignancies (ZUMA-25) - Substudy B - Relapsed/Refractory Richter Transformation | No dispute reported | 06/30/2026 | 1212066808 |
| Principal investigator 1 | Kite Pharma, Inc. | $13,466.00 | 01/28/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel in Adults with Rare B-cell Malignancies (ZUMA-25) - Substudy B - Relapsed/Refractory Richter Transformation | No dispute reported | 06/30/2026 | 1212066812 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $1,164.99 | 01/27/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Phase 2 Randomized, Open Label Study to Evaluate the Efficacy and Safety of Golcadomide in Combination with Rituximab in Patients with Newly Diagnosed Advanced Stage Follicular Lymphoma | No dispute reported | 06/30/2026 | 1236001118 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,550.00 | 01/23/2025 | Covered Recipient Teaching Hospital Jersey Shore University Med Ctr | A Randomized Open label Phase 3 study of the Combination of Ibrutinib plus Venetoclax versus Chlorambucil plus Obinutuzumab for the Firstline Treatment of Subjects with Chronic Lymphocytic Leukemia CLL Small Lymphocytic Lymphoma SLL | No dispute reported | 06/30/2026 | 1175337830 |
| Principal investigator 1 | Eli Lilly and Company | $205,205.54 | 01/22/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF FIXED DURATION PIRTOBRUTINIB (LOXO-305) PLUS VENETOCLAX AND RITUXIMAB VERSUS VENETOCLAX AND RITUXIMAB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (BRUIN CLL-322) | No dispute reported | 06/30/2026 | 1187873719 |
| Principal investigator 1 | Genmab A/S | $480.00 | 01/22/2025 | Non-covered Recipient Entity HACKENSACK MERIDIAN HEALTH HACKENSACK UNIVERSITY MEDICAL CENTER | A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. | No dispute reported | 06/30/2026 | 1235930307 |
| Principal investigator 1 | Kite Pharma, Inc. | $1,521.00 | 01/22/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A PHASE 2 OPEN-LABEL, MULTICENTER STUDY EVALUATING THE SAFETY AND EFFICACY OF AXICABTAGENE-CILOLEUCEL CONCOMITANT WITH PROPHYLACTIC STEROIDS IN SUBJECTS WITH RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA IN THE OUTPATIENT SETTING | No dispute reported | 06/30/2026 | 1212066858 |
| Principal investigator 1 | BeiGene, Ltd. | $9,877.00 | 01/21/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1190321544 |
| Principal investigator 1 | BeiGene, Ltd. | $1,200.00 | 01/21/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Phase 1a/1b Open-Label Dose Escalation and Expansion Study of Bcl-2 Inhibitor BGB-11417 in Patients With Mature B-Cell Malignancies | No dispute reported | 06/30/2026 | 1190322682 |
| Principal investigator 1 | BeiGene, Ltd. | $2,400.00 | 01/21/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Phase 1a/1b Open-Label Dose Escalation and Expansion Study of Bcl-2 Inhibitor BGB-11417 in Patients With Mature B-Cell Malignancies | No dispute reported | 06/30/2026 | 1190322684 |
| Principal investigator 1 | Kite Pharma, Inc. | $1,275.00 | 01/21/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A PHASE 2 OPEN-LABEL, MULTICENTER STUDY EVALUATING THE SAFETY AND EFFICACY OF AXICABTAGENE-CILOLEUCEL CONCOMITANT WITH PROPHYLACTIC STEROIDS IN SUBJECTS WITH RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA IN THE OUTPATIENT SETTING | No dispute reported | 06/30/2026 | 1212066848 |
| Principal investigator 1 | Kite Pharma, Inc. | $600.00 | 01/21/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (ZUMA 5) | No dispute reported | 06/30/2026 | 1212066853 |
| Principal investigator 1 | Kite Pharma, Inc. | $6,120.00 | 01/14/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A PHASE 2 OPEN-LABEL, MULTICENTER STUDY EVALUATING THE SAFETY AND EFFICACY OF AXICABTAGENE-CILOLEUCEL CONCOMITANT WITH PROPHYLACTIC STEROIDS IN SUBJECTS WITH RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA IN THE OUTPATIENT SETTING | No dispute reported | 06/30/2026 | 1212066843 |
| Principal investigator 1 | Celgene Corporation | $221,244.02 | 01/13/2025 | Covered Recipient Teaching Hospital Jfk University Medical Center | A Phase 2 Randomized, Open Label Study to Evaluate the Efficacy and Safety of Golcadomide in Combination with Rituximab in Patients with Newly Diagnosed Advanced Stage Follicular Lymphoma | No dispute reported | 06/30/2026 | 1222304477 |
| Principal investigator 1 | Genmab A/S | $960.00 | 01/10/2025 | Non-covered Recipient Entity HACKENSACK MERIDIAN HEALTH HACKENSACK UNIVERSITY MEDICAL CENTER | A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. | No dispute reported | 06/30/2026 | 1235930372 |
| Principal investigator 1 | Genmab A/S | $400.00 | 01/10/2025 | Non-covered Recipient Entity HACKENSACK MERIDIAN HEALTH HACKENSACK UNIVERSITY MEDICAL CENTER | A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody-CD3 X CD20) in Relapsed/Refractory Chronic Lymphocytic Leukemia. | No dispute reported | 06/30/2026 | 1235930376 |
| Principal investigator 1 | BeiGene, Ltd. | $90,720.00 | 01/08/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Phase 1a/1b Open-Label Dose Escalation and Expansion Study of Bcl-2 Inhibitor BGB-11417 in Patients With Mature B-Cell Malignancies | No dispute reported | 06/30/2026 | 1190321810 |
| Principal investigator 1 | BeiGene, Ltd. | $1,000.00 | 01/06/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Phase 1a/1b Open-Label Dose Escalation and Expansion Study of Bcl-2 Inhibitor BGB-11417 in Patients With Mature B-Cell Malignancies | No dispute reported | 06/30/2026 | 1190322680 |
| Principal investigator 1 | BeiGene, Ltd. | $500.00 | 01/06/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Phase 1a/1b Open-Label Dose Escalation and Expansion Study of Bcl-2 Inhibitor BGB-11417 in Patients With Mature B-Cell Malignancies | No dispute reported | 06/30/2026 | 1190322686 |
| Principal investigator 1 | Genmab A/S | $213.00 | 01/06/2025 | Non-covered Recipient Entity HACKENSACK MERIDIAN HEALTH HACKENSACK UNIVERSITY MEDICAL CENTER | A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. | No dispute reported | 06/30/2026 | 1235930320 |
| Principal investigator 1 | Genmab A/S | $2,720.00 | 01/06/2025 | Non-covered Recipient Entity HACKENSACK MERIDIAN HEALTH HACKENSACK UNIVERSITY MEDICAL CENTER | A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. | No dispute reported | 06/30/2026 | 1235930324 |
| Principal investigator 1 | Genmab A/S | $282.00 | 01/06/2025 | Non-covered Recipient Entity HACKENSACK MERIDIAN HEALTH HACKENSACK UNIVERSITY MEDICAL CENTER | A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. | No dispute reported | 06/30/2026 | 1235930336 |
| Principal investigator 1 | Genmab A/S | $2,720.00 | 01/06/2025 | Non-covered Recipient Entity HACKENSACK MERIDIAN HEALTH HACKENSACK UNIVERSITY MEDICAL CENTER | A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. | No dispute reported | 06/30/2026 | 1235930358 |
| Principal investigator 1 | Genmab A/S | $477.20 | 01/06/2025 | Non-covered Recipient Entity HACKENSACK MERIDIAN HEALTH HACKENSACK UNIVERSITY MEDICAL CENTER | A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. | No dispute reported | 06/30/2026 | 1235930384 |